UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Apple Turns 50: From Garage Startup to AI Crossroads 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Britain Courts Anthropic Amid US Defense Department Dispute 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
GAITHERSBURG, Md., Nov. 30, 2016 -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will participate in the Citi 2016 Global Healthcare Conference.
Conference details are as follows:
Date: Wednesday, December 7, 2016
Location: New York Palace Hotel, New York, New York
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Associate Director, Investor Relations [email protected] 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] [email protected] 212-845-4271
